Recombinant Human Growth Hormone Drug Class List

Drugs in Drug Class: Recombinant Human Growth Hormone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Market Dynamics and Patent Landscape for Recombinant Human Growth Hormone (rhGH)

Last updated: April 14, 2026

What Are the Market Drivers and Challenges for rhGH?

The recombinant human growth hormone (rhGH) market is characterized by steady growth driven by expanding therapeutic indications, increasing demand in pediatric and adult growth deficiencies, and advances in biotechnology.

Market Size and Growth

• The global rhGH market was valued at approximately USD 4.5 billion in 2022.
• Compound annual growth rate (CAGR) projected at 4.5% from 2023 to 2030.
• Growth is driven by rising diagnoses of growth hormone deficiency (GHD), Turner syndrome, and other off-label uses such as aging.

Key Commercial Drivers

• Increasing incidence of GHD and related conditions.
• Launch of biosimilar rhGH products reducing treatment costs.
• Growth in adult GHD treatment segments, particularly in North America and Europe.
• Improving healthcare infrastructure and greater awareness.

Market Challenges

• Patent expiration of key brands, leading to biosimilar competition.
• Strict regulatory pathways for biosimilar approval.
• Limited penetration in emerging markets due to cost constraints.
• Concerns regarding biosimilar interchangeability and immunogenicity.

How Does the Patent Landscape for rhGH Evolve?

The patent landscape for rhGH is complex, with primary patents covering manufacturing processes, formulations, and delivery methods. The expiration of foundational patents has accelerated biosimilar entries.

Major Patents and Their Expiration

• Genentech’s Norditropin (somatropin) held key patents through 2015.
• Pfizer’s Genotropin and Eli Lilly’s Humatrope had patents expiring between 2014 and 2017.
• Recent patents for specific formulations or delivery devices extend protection further into the 2020s.

Patent Holder	Patent Type	Key Patent Expiry	Notes
Genentech (Novartis)	Composition/formulation	2015	Norditropin patents expired, enabling biosimilar competition.
Pfizer	Delivery device	2017	Spin the patent landscape for biosimilars.
Eli Lilly	Method of manufacturing	2014	Led to biosimilar developments post-expiry.

Biosimilar Development Landscape

• Several biosimilars approved or in late-stage development post-2015.
• Notable biosimilars approved include Sandoz's Omnitrope (approved in 2006, but expanded patents in subsequent years).
• Patent litigation and opposition remain active, limiting market entry timelines.

Patent Strategies

• Companies extend patent life via secondary filings, formulations, and delivery innovations.
• Some firms pursue patent thickets to delay biosimilar entry.
• Patent expirations have catalyzed growth but are countered by legal defenses.

What Are the Regulatory and IP Trends?

• Regulatory approvals for biosimilars in the U.S. began in 2015 post-approval of Sandoz’s Omnitrope.
• The FDA’s pathway for biosimilar approval requires demonstrating similarity through analytical, non-clinical, and clinical data.
• Patent linkage systems in Europe (Supplementary Protection Certificates) provide additional protection.
• Ongoing patent litigations impact biosimilar market entry timelines.

Key Players and Competitive Dynamics

Company	Market Share (2022)	Focus Areas	Notable Patents
Pfizer	~30%	Original biologics, biosimilars	Delivery devices, formulations
Novo Nordisk	~15%	Growth hormone formulations	Delivery device innovations
Sandoz (Novartis)	Growing	Biosimilars	Formulation, manufacturing patents
Eli Lilly	~10%	Established biologic products	Manufacturing process patents

Market leaders seek to balance patent exclusivity with biosimilar competition, often engaging in patent litigation or settlement agreements.

Future Outlook and Innovation Trends

• Development of long-acting rhGH formulations to improve adherence.
• Advances in delivery technology, including auto-injectors and novel delivery devices.
• Entry of gene therapy and alternative biologics reducing reliance on traditional rhGH.
• Patent strategies emphasizing formulations, delivery methods, and manufacturing processes.

Key Takeaways

• The rhGH market is growing modestly, fueled by expanded indications and biosimilar competition post-2015 patent expirations.
• Patent landscape is dynamic, with primary patents expiring and secondary patents extending protection.
• Biosimilar entry is influenced by regulatory, legal, and patent strategies, impacting market competition.
• Innovation focuses on delivery and formulation improvements to prolong market relevance.
• Emerging markets and aging populations present growth opportunities despite regulatory challenges.

FAQs

1. When are key patents for brand-name rhGH products expected to expire?
Most primary patents expired between 2014 and 2017, allowing biosimilar development to accelerate.

2. How do biosimilar rhGH products differ from original biologics?
They are required to demonstrate high similarity in efficacy and safety but may differ in excipients or delivery devices.

3. What regulatory pathways exist for biosimilar approval?
In the U.S., the FDA’s 351(k) pathway requires demonstrating biosimilarity through analytical, clinical, and pharmacokinetic studies.

4. Which companies dominate the biosimilar rhGH market?
Sandoz (Novartis), generic manufacturers like Teva, and emerging regional players.

5. What innovations are expected in rhGH therapy?
Long-acting formulations, improved delivery devices, and potential gene therapy integrations.

---

References

[1] MarketsandMarkets. (2023). Human Growth Hormone Market by Product Type, Application, and Region.
[2] U.S. Food and Drug Administration. (2015). Biosimilar Product Development and Approval.
[3] European Medicines Agency. (2022). Biosimilar Medicines in the EU.
[4] Patent Scope. World Intellectual Property Organization. (2023). RhGH patents.
[5] Frost & Sullivan. (2022). Global Biosimilar Market Analysis.